Literature DB >> 20973588

First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA.

Iztok Turel1, Jakob Kljun, Franc Perdih, Elena Morozova, Vladimir Bakulev, Nina Kasyanenko, Jo Ann W Byl, Neil Osheroff.   

Abstract

An organometallic ruthenium complex of quinolone antibacterial agent ofloxacin, [(η(6)-p-cymene)RuCl(O,O-oflo)]·2.8H(2)O (1·2.8H(2)O), was isolated, and its crystal structure was determined. In this "piano-stool" complex, quinolone is bidentately coordinated to the metal through the ring carbonyl and one of the carboxylic oxygen atoms. Interactions of the title complex with DNA were studied by spectroscopic methods [electronic, fluorescence, and circular dichroism (CD)] and atomic force microscopy (AFM). It was established that the electrostatic attraction between the ruthenium complex and DNA in a solution is important for binding because interactions were observed only in a solution with low ionic strengths. An induced-CD (ICD) signal was observed in a solution of DNA and the title complex, which proves interaction between ruthenium and macromolecules. Competitive binding between cisplatin and 1 to DNA revealed that cisplatin prevents binding of 1. Our experiments revealed that binding of the title complex to DNA occurs also if guanine N7 is protonated. AFM has shown that the title complex provokes DNA shrinkage. Preliminary biological tests have also been performed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20973588      PMCID: PMC3698415          DOI: 10.1021/ic101355d

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  15 in total

Review 1.  Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.

Authors:  Lester A Mitscher
Journal:  Chem Rev       Date:  2005-02       Impact factor: 60.622

2.  Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding.

Authors:  Anna F A Peacock; Michael Melchart; Robert J Deeth; Abraha Habtemariam; Simon Parsons; Peter J Sadler
Journal:  Chemistry       Date:  2007       Impact factor: 5.236

3.  X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones - racemic ofloxacin and its S-form, levofloxacin.

Authors:  Petra Drevensek; Janez Kosmrlj; Gerald Giester; Tormod Skauge; Einar Sletten; Kristina Sepcić; Iztok Turel
Journal:  J Inorg Biochem       Date:  2006-07-04       Impact factor: 4.155

4.  Mononuclear metal complexes with piroxicam: synthesis, structure and biological activity.

Authors:  Petros Christofis; Maria Katsarou; Athanasios Papakyriakou; Yiannis Sanakis; Nikos Katsaros; George Psomas
Journal:  J Inorg Biochem       Date:  2005-09-19       Impact factor: 4.155

Review 5.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

Authors:  Christian G Hartinger; Stefanie Zorbas-Seifried; Michael A Jakupec; Bernd Kynast; Haralabos Zorbas; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2006-02-28       Impact factor: 4.155

6.  Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.

Authors:  Alexandre Wohlkonig; Pan F Chan; Andrew P Fosberry; Paul Homes; Jianzhong Huang; Michael Kranz; Vaughan R Leydon; Timothy J Miles; Neil D Pearson; Rajika L Perera; Anthony J Shillings; Michael N Gwynn; Benjamin D Bax
Journal:  Nat Struct Mol Biol       Date:  2010-08-29       Impact factor: 15.369

7.  Mechanism of differential activities of ofloxacin enantiomers.

Authors:  I Morrissey; K Hoshino; K Sato; A Yoshida; I Hayakawa; M G Bures; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

Authors:  Jeany M Rademaker-Lakhai; Desiree van den Bongard; Dick Pluim; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin.

Authors:  Sanja Grguric-Sipka; Iryna N Stepanenko; Jelena M Lazic; Caroline Bartel; Michael A Jakupec; Vladimir B Arion; Bernhard K Keppler
Journal:  Dalton Trans       Date:  2009-03-12       Impact factor: 4.390

10.  Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

Authors:  Haimei Chen; John A Parkinson; Robert E Morris; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2003-01-08       Impact factor: 15.419

View more
  11 in total

1.  Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes.

Authors:  Zuzana Sochorová Vokáčová; Iztok Turel; Jaroslav V Burda
Journal:  J Mol Model       Date:  2018-03-20       Impact factor: 1.810

2.  Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones.

Authors:  Jakob Kljun; Anna K Bytzek; Wolfgang Kandioller; Caroline Bartel; Michael A Jakupec; Christian G Hartinger; Bernhard K Keppler; Iztok Turel
Journal:  Organometallics       Date:  2011-04-06       Impact factor: 3.876

3.  Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.

Authors:  Lukas K Filak; Danuta S Kalinowski; Theresa J Bauer; Des R Richardson; Vladimir B Arion
Journal:  Inorg Chem       Date:  2014-06-13       Impact factor: 5.165

4.  Molecular aspect on the interaction of zinc-ofloxacin complex with deoxyribonucleic acid, proposed model for binding and cytotoxicity evaluation.

Authors:  F Ahmadi; N Ebrahimi-Dishabi; K Mansouri; F Salimi
Journal:  Res Pharm Sci       Date:  2014 Sep-Oct

5.  Norfloxacin and N-Donor Mixed-Ligand Copper(II) Complexes: Synthesis, Albumin Interaction, and Anti-Trypanosoma cruzi Activity.

Authors:  Darliane A Martins; Ligiane R Gouvea; Gabriel S Vignoli Muniz; Sonia R W Louro; Denise da Gama Jaen Batista; Maria de Nazaré C Soeiro; Letícia R Teixeira
Journal:  Bioinorg Chem Appl       Date:  2016-01-26       Impact factor: 7.778

6.  Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity.

Authors:  Nichola A Smith; Pingyu Zhang; Simon E Greenough; Michael D Horbury; Guy J Clarkson; Daniel McFeely; Abraha Habtemariam; Luca Salassa; Vasilios G Stavros; Christopher G Dowson; Peter J Sadler
Journal:  Chem Sci       Date:  2016-08-30       Impact factor: 9.825

Review 7.  Metal complexes of quinolone antibiotics and their applications: an update.

Authors:  Valentina Uivarosi
Journal:  Molecules       Date:  2013-09-11       Impact factor: 4.411

8.  Microwave-assisted synthesis of ruthenium(ii) complexes containing levofloxacin-induced G2/M phase arrest by triggering DNA damage.

Authors:  Ruotong Liu; Chanling Yuan; Yin Feng; Jiayi Qian; Xiaoting Huang; Qiutong Chen; Shuyuan Zhou; Yin Ding; Bingbing Zhai; Wenjie Mei; Liangzhong Yao
Journal:  RSC Adv       Date:  2021-01-22       Impact factor: 3.361

9.  Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE.

Authors:  Jerneja Kladnik; Samuel Ristovski; Jakob Kljun; Andrea Defant; Ines Mancini; Kristina Sepčić; Iztok Turel
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

10.  Comparing the suitability of autodock, gold and glide for the docking and predicting the possible targets of Ru(II)-based complexes as anticancer agents.

Authors:  Adebayo A Adeniyi; Peter A Ajibade
Journal:  Molecules       Date:  2013-03-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.